Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry …
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
view original post